Geissler F, Anderson S K, Venkatesan P, Press O
Department of Biological Structure, University of Washington, Seattle 98195.
Cancer Res. 1992 May 15;52(10):2907-15.
The endocytosis and degradation of 125I-labeled anti-mu monoclonal antibody DA4-4 by a Burkitt's lymphoma cell line was investigated using biochemical, chromatographic, electrophoretic, radioautographic, and electron microscopic techniques. 125I-DA4-4 was rapidly internalized by Ramos cells and routed from endosomes to lysosomes. Proteolysis of radiolabeled antibodies began in a late endosomal compartment, but lysosomes were primarily responsible for the terminal degradation of 125I-DA4-4. Catabolism of 125I-DA4-4 could be inhibited by 74-95% by blocking its delivery to late endosomes and lysosomes by incubation at 18 degrees C, by neutralizing the pH in intracellular organelles with monensin or ammonium chloride, or by inhibiting lysosomal enzymes with leupeptin. Radiolabeled antibodies synthesized using the chloramine T or Iodo-Gen techniques were degraded three times faster than conjugates made using a nonmetabolizable 125I-tyramine cellobiose adduct. Five major intermediate metabolites (Mr 48,000, 42,000, 25,000, 15,000, and 10,000) were generated during the intracellular catabolism of 125I-DA4-4, but 125I-tyrosine was responsible for 95% of the small-molecular-weight metabolites released by cells into the culture medium. We anticipate that a full comprehension of the catabolism of radiolabeled antibodies by tumor cells will make possible the development of clinical interventions which will enhance the retention of radioimmunoconjugates by hematologic malignancies and improve the efficacy of radioimmunotherapy.
运用生化、色谱、电泳、放射自显影及电子显微镜技术,对伯基特淋巴瘤细胞系摄取及降解¹²⁵I标记的抗μ单克隆抗体DA4-4的过程进行了研究。¹²⁵I-DA4-4被Ramos细胞迅速内化,并从内体转运至溶酶体。放射性标记抗体的蛋白水解始于晚期内体区室,但溶酶体是¹²⁵I-DA4-4最终降解的主要场所。通过在18℃孵育阻断其向晚期内体和溶酶体的转运、用莫能菌素或氯化铵中和细胞内细胞器的pH值,或用亮抑酶肽抑制溶酶体酶,¹²⁵I-DA4-4的分解代谢可被抑制74%至95%。用氯胺T或碘甘醚技术合成的放射性标记抗体的降解速度比使用不可代谢的¹²⁵I-酪胺纤维二糖加合物制备的缀合物快三倍。¹²⁵I-DA4-4细胞内分解代谢过程中产生了五种主要中间代谢产物(分子量分别为48,000、42,000、25,000、15,000和10,000),但¹²⁵I-酪氨酸占细胞释放到培养基中的小分子代谢产物的95%。我们预计,全面了解肿瘤细胞对放射性标记抗体的分解代谢将有助于开发临床干预措施,提高血液系统恶性肿瘤对放射免疫缀合物的保留率,并提高放射免疫治疗的疗效。